Back to News
Market Impact: 0.2
Autonomix Medical Receives European Patent For Neural Activity Assessment Technology
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & BiotechTechnology & Innovation
Autonomix Medical (AMIX) received European Patent No. EP 4 233 700 B1 for systems assessing neural activity in the eye. The patent expands European intellectual-property protection for the company’s autonomic nervous system assessment and precision neuromodulation technologies, a modest positive for its technology platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AMIX0.60
More News
- Trump Versus Xi: How Their High-Stakes Summits Compare
- Trump, Xi Address AI, Taiwan During State Visit
- Oracle Japan shares surge 7% after record fiscal first quarter, bucking selloff of U.S. parent
- China's Xi urges U.S. to cooperate on AI
- Akamai secures $11.6B cloud deal with Anthropic for AI workloads
- U.S. government seeks to join Elon Musk in challenge against EU's fine on X